Your session is about to expire
← Back to Search
DCA for Glioblastoma
Study Summary
This trial will test the effects of the drug DCA on brain cancer patients who are undergoing surgery. Patients will be given DCA or a placebo for one week before surgery, and then blood and tumor tissue will be collected and analyzed.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I've had surgery, radiation, and TMZ for my cancer but it didn't work. If my GBM is unmethylated, I haven't had TMZ.I am being treated at Johns Hopkins or Wake Forest University and can take my current medications, except insulin or sulfonylureas.I am not at risk for drug interactions with DCA based on its unique metabolism and past trial data.I am diabetic with a recent Hgb A1c level of 6.0 or higher.I am an adult between 18 and 80 with a GBM diagnosis, my tumor has come back, and I have symptoms like headaches or seizures. Surgery to remove the tumor is planned.My liver functions well (bilirubin ≤ 2.0 mg/dl, ALT and AST ≤ 3 times the upper limit).I am not taking insulin or sulfonylurea for my type 2 diabetes.My kidney function is good (GFR > 30 ml/min).
- Group 1: No Pre-Surgical Dichloroacetate (DCA)
- Group 2: Pre-Surgical Dichloroacetate (DCA)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current population size of this research program?
"That is correct. The details on clinicaltrials.gov demonstrate that this experiment, which was initially released on July 1st 2022, is still ongoing. A total of 40 patients are needed from 2 distinct medical centres."
Has the FDA permitted the non-surgical use of Dichloroacetate (DCA)?
"Our organization at Power graded the safety of No Pre-Surgical Dichloroacetate (DCA) as a 2, given that it is currently in its second phase. This implies there exists some data regarding security but none to prove efficacy."
Is this research unique or has it been previously explored?
"Since 2020, No Pre-Surgical Dichloroacetate (DCA) has been subject to clinical investigation. Medosome Biotec LLC sponsored the first trial with 34 participants, which granted the drug its Phase 3 approval. At present, three ongoing trials are recruiting patients across 10 cities and one nation."
Is the age bracket for this experimental research extending beyond twenty years?
"The parameters of this trial necessitate enrolment from individuals between 18 and 80. 36 studies are available to minors, while those over 65 have access to 418 different trials."
Is enrollment open for this trial at present?
"That is correct. According to clinicaltrials.gov, recruitment for this medical trial began on the 1st of July 2022 and was recently updated on August 26th, 2022. The study seeks 40 individuals from two separate locations."
What other experiments have been conducted to explore the potential of No Pre-Surgical Dichloroacetate (DCA)?
"Presently, there are 3 running trials on No Pre-Surgical Dichloroacetate (DCA) with 1 in Phase 3. 12 different medical centres across the country have studies involving this drug; however, most of them are located at Stanford University in California."
Is enrollment open to join this experiment?
"This medical trial is currently enrolling 40 patients, aged 18-80 years old with a glioblastoma diagnosis. All participants must meet several criteria: they will be recruited and studied at 11 ABTC clinical sites, the DCA liquid formulation has been approved by the FDA for oral or feeding tube administration; insulin or sulfonylurea therapy are not permitted but other medications may remain unchanged; male and female adults between 18 - 80 years of age who have experienced GBM recurrence combined with symptomatology (e.g., headache) can apply, having completed standard treatment followed by radiation and temozolomide in"
Share this study with friends
Copy Link
Messenger